Sonoma Pharmaceuticals Delivers 141% U.S. Revenue Growth in FY Q1, 60% Total Revenue Growth and First-Ever Positive Adjusted EBITDA
Rhea-AI Summary
Sonoma Pharmaceuticals (NASDAQ:SNOA) reported fiscal Q1 2027 revenue of $6.4 million, up 60% year over year, driven by a 141% increase in U.S. sales and growth across Europe, Asia, Latin America and Rest of World.
Gross profit rose to $2.6 million with gross margin expanding to 40% from 36%, while operating expenses held essentially flat at $2.6 million. GAAP net loss narrowed to $0.33 million from $1.24 million, and EBITDA turned positive to about $0.05 million, marking the company’s first positive EBITDA quarter. Non-GAAP net income was $0.07 million. As of June 30, 2026, cash and equivalents were $5.3 million.
According to Sonoma Pharmaceuticals, growth was supported by a new FDA 510(k) clearance for Microdacyn Wound Irrigation Solution with expanded claims and multi-use clearance, plus new distributors added in Taiwan, Vietnam and the United States.
Positive
- Total revenue up 60% YoY to $6.4 million in Q1 2027
- U.S. revenue increased 141% YoY, adding $1.4 million
- Gross margin expanded to 40% from 36% year over year
- GAAP net loss reduced to $0.33 million from $1.24 million
- EBITDA turned positive to approximately $0.05 million from a $1.0 million loss
- Cash balance increased to $5.3 million from $2.4 million at March 31, 2026
- Non-GAAP net income reached $0.07 million versus a $0.60 million loss
- New FDA 510(k) clearance for Microdacyn Wound Irrigation Solution with expanded claims and multi-use
- New distributors added in Taiwan, Vietnam and the United States
Negative
- Company remains loss-making with GAAP net loss of $0.33 million
- Other expense increased to $0.29 million from $0.15 million year over year
- Accumulated deficit stands at $201.3 million as of June 30, 2026
- Withholding tax payable totals $5.6 million, exceeding current net income metrics
- Share count rose from 1.80 million to 4.79 million QoQ, indicating substantial dilution
News Explained
The reported common-share base was 4,785,801 at June 30, up from 1,799,057 at March 31, while cash was $5.338 million.
Sonoma Pharmaceuticals has reported results for the quarter ended
At
Sources and calculations
- Sonoma Pharmaceuticals first-quarter fiscal 2027 results release (2026-08-06)
- Sonoma Pharmaceuticals fiscal 2027 first-quarter fundamentals (2027Q1)
- Cash and equivalents vs quarterly operating cash outflow, in days of cash use $5,338,000 / ($649,000 / 90) = [object Object]
Market reaction after FY Q1 earnings report: SNOA +10.62% in the Aug 6 session
In the Aug 6 session, SNOA gained 10.62%, reflecting a significant positive market reaction. Argus tracked a peak move of +10.2% during that session. Our momentum scanner triggered 14 alerts that day, indicating notable trading interest and price volatility. Trading volume was exceptionally heavy at 22.3x the daily average, suggesting very strong buying interest.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Jun 30 | FDA clearance | Positive | +0.0% | FDA clearance expanded Microdacyn wound-solution indications, uses, and packaging options |
| Jun 16 | FY earnings | Positive | +4.5% | Fiscal fourth-quarter revenue growth accompanied narrowed net and EBITDA losses |
| Apr 24 | Public offering | Negative | -36.7% | Company priced a firm-commitment offering of shares and warrants |
| Mar 24 | Product launch | Positive | -8.2% | Advanced burn-relief hydrogel launched through CVS and Walmart distribution |
| Mar 18 | Product launch | Positive | +2.9% | Aquanil AD dermatology line launched for U.S. over-the-counter distribution |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
The historical record showed that positive earnings and product news did not consistently align with price reactions, while the prior offering reaction was sharply negative.
Key Terms
510(k) regulatory
hypochlorous acid (hocl) medical
ebitda financial
non-gaap financial measure financial
AI-generated analysis. How Rhea-AI works. Not financial advice.
Total revenue increased
60% year over year to$6.4 million Net loss per share decreased
88% compared to the prior-year quarterGross margin expanded to
40% as operating expenses remained stableFDA clearance and new global distributors support continued commercial growth
BOULDER, CO / ACCESS Newswire / August 6, 2026 / Sonoma Pharmaceuticals, Inc. (NASDAQ:SNOA), a global healthcare leader developing and producing patented Microcyn® technology-based stabilized hypochlorous acid (HOCl) products for a wide range of applications including wound care, eye care, dermatological conditions, podiatry, animal health care and non-toxic disinfectants, today announced financial results for its first fiscal quarter ended June 30, 2026.
"Our first quarter results demonstrate that Sonoma has reached an important inflection point," said Amy Trombly, CEO of Sonoma. "We delivered record quarterly revenue, more than doubled our U.S. business, expanded gross margins to
Business Highlights
Sonoma continued to expand regulatory approvals and grow its global distribution network:
In June 2026, Sonoma received a new 510(k) clearance from the U.S. Food and Drug Administration (FDA) for its Microdacyn® Wound Irrigation Solution, including expanded claims, clearance for multiple use, and additional packaging configurations.
Since the start of fiscal year 2027, Sonoma has added new distributors to its network in Taiwan, Vietnam and the United States.
Results for the Quarter Ended June 30, 2026
Total revenues for the quarter ended June 30, 2026 of
During the quarter ended June 30, 2026, Sonoma reported revenues of
Total operating expenses during the quarter ended June 30, 2026 were
Net loss for the quarter ended June 30, 2026 of
As of June 30, 2026, Sonoma had cash and cash equivalents of
About Sonoma Pharmaceuticals, Inc.
Sonoma Pharmaceuticals is a global healthcare leader for developing and producing stabilized hypochlorous acid (HOCl) products for a wide range of applications, including wound care, eye care, dermatological conditions, podiatry, animal health care and non-toxic disinfectants. The company's products are clinically proven to reduce itch, pain, scarring, and irritation safely and without damaging healthy tissue. In-vitro and clinical studies of HOCl show it to safely manage skin abrasions, lacerations, minor irritations, cuts, and intact skin. The company's products are sold either directly or via partners in over 55 countries worldwide and the company actively seeks new distribution partners. The company's principal office is in Boulder, Colorado, with manufacturing operations in Guadalajara, Mexico. European marketing and sales are headquartered in Roermond, Netherlands. More information can be found at www.sonomapharma.com. For partnership opportunities, please contact businessdevelopment@sonomapharma.com.
Forward-Looking Statements
Except for historical information herein, matters set forth in this press release are forward-looking within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995, including statements about the commercial and technology progress and future financial performance of Sonoma Pharmaceuticals, Inc. and its subsidiaries (the "company"). These forward-looking statements are identified by the use of words such as "continue," "reduce," "develop," "aim," and "expand," among others. Forward-looking statements in this press release are subject to certain risks and uncertainties inherent in the company's business that could cause actual results to vary, including such risks that regulatory clinical and guideline developments may change, scientific data may not be sufficient to meet regulatory standards or receipt of required regulatory clearances or approvals, clinical results may not be replicated in actual patient settings, protection offered by the company's patents and patent applications may be challenged, invalidated or circumvented by its competitors, the available market for the company's products will not be as large as expected, the company's products will not be able to penetrate one or more targeted markets, revenues will not be sufficient to meet the company's cash needs or fund further development, as well as uncertainties relative to the recent pandemic and economic development, varying product formulations and a multitude of diverse regulatory and marketing requirements in different countries and municipalities, and other risks detailed from time to time in the company's filings with the Securities and Exchange Commission. The company disclaims any obligation to update these forward-looking statements, except as required by law.
Sonoma Pharmaceuticals™ Microcyn® and Microdacyn® are trademarks or registered trademarks of Sonoma Pharmaceuticals, Inc. All other trademarks and service marks are the property of their respective owners.
Media and Investor Contact:
Sonoma Pharmaceuticals, Inc.
Website: www.sonomapharma.com
Follow us on LinkedIn: https://www.linkedin.com/company/sonoma-pharmaceuticals
Follow us on Instagram: https://www.instagram.com/sonomapharma_us/
Follow us on Facebook: https://www.facebook.com/sonomapharma/
SONOMA PHARMACEUTICALS, INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED BALANCE SHEETS
(In thousands, except share amounts)
June 30, | March 31, | |||||||
2026 | 2026 | |||||||
(Unaudited) | ||||||||
ASSETS | ||||||||
Current assets: | ||||||||
Cash and cash equivalents | $ | 5,338 | $ | 2,399 | ||||
Accounts receivable, net | 3,182 | 2,527 | ||||||
Inventories, net | 3,786 | 3,651 | ||||||
Prepaid expenses and other current assets | 3,962 | 3,523 | ||||||
Total current assets | 16,268 | 12,100 | ||||||
Property and equipment, net | 290 | 310 | ||||||
Operating lease, right of use assets | 578 | 602 | ||||||
Deferred tax asset, net | 905 | 884 | ||||||
Other assets | 66 | 64 | ||||||
Total assets | $ | 18,107 | $ | 13,960 | ||||
LIABILITIES AND STOCKHOLDERS' EQUITY | ||||||||
Current liabilities: | ||||||||
Accounts payable | $ | 2,191 | $ | 1,923 | ||||
Accrued expenses and other current liabilities | 2,674 | 2,252 | ||||||
Deferred revenue | 282 | 284 | ||||||
Short-term debt | 140 | 222 | ||||||
Operating lease liabilities, current portion | 160 | 151 | ||||||
Total current liabilities | 5,447 | 4,832 | ||||||
Withholding tax payable | 5,627 | 5,564 | ||||||
Operating lease liabilities, less current portion | 439 | 469 | ||||||
Total liabilities | 11,513 | 10,865 | ||||||
Commitments and Contingencies | ||||||||
Stockholders' Equity: | ||||||||
Convertible preferred stock, | - | - | ||||||
Common stock, | - | - | ||||||
Additional paid-in capital | 210,913 | 207,319 | ||||||
Accumulated deficit | (201,311 | ) | (200,981 | ) | ||||
Accumulated other comprehensive loss | (3,008 | ) | (3,243 | ) | ||||
Total stockholders' equity | 6,594 | 3,095 | ||||||
Total liabilities and stockholders' equity | $ | 18,107 | $ | 13,960 | ||||
SONOMA PHARMACEUTICALS, INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS
(In thousands, except per share amounts)
(Unaudited)
Three Months Ended June 30, | ||||||||
2026 | 2025 | |||||||
Revenues | $ | 6,406 | $ | 4,015 | ||||
Cost of revenues | 3,829 | 2,551 | ||||||
Gross profit | 2,577 | 1,464 | ||||||
Operating expenses: | ||||||||
Research and development | 597 | 594 | ||||||
Selling, general and administrative | 2,020 | 1,965 | ||||||
Total operating expenses | 2,617 | 2,559 | ||||||
Loss from operations | (40 | ) | (1,095 | ) | ||||
Other expense, net | (290 | ) | (147 | ) | ||||
Loss from operations before income taxes | (330 | ) | (1,242 | ) | ||||
Income tax benefit | 1 | |||||||
Net loss | $ | (330 | ) | $ | (1,241 | ) | ||
Net loss per share: basic and diluted | $ | (0.09 | ) | $ | (0.76 | ) | ||
Weighted-average shares outstanding: basic and diluted | 3,846 | 1,641 | ||||||
Other comprehensive loss: | ||||||||
Net loss | $ | (330 | ) | $ | (1,241 | ) | ||
Foreign currency translation adjustments | 235 | 806 | ||||||
Comprehensive loss | $ | (95 | ) | $ | (435 | ) | ||
SONOMA PHARMACEUTICALS, INC. AND SUBSIDIARIES
RECONCILIATION OF GAAP MEASURES TO NON-GAAP MEASURES
(In thousands)
(Unaudited)
Three Months Ended June 30, | ||||||||
2026 | 2025 | |||||||
(1) Loss from operations adjusted for non-cash items and one-time events, or EBITDA loss: | ||||||||
GAAP loss from operations as reported | $ | (40 | ) | $ | (1,095 | ) | ||
Non-cash adjustments: | ||||||||
Stock-based compensation | 58 | 57 | ||||||
Depreciation | 32 | 36 | ||||||
Non-GAAP loss from operations minus non-cash expenses EBITDA gain (loss) | $ | 50 | $ | (1,002 | ) | |||
(2) Net loss adjusted for non-cash items and one-time events: | ||||||||
GAAP net loss as reported | $ | (330 | ) | $ | (1,241 | ) | ||
Non-cash adjustments: | ||||||||
Stock-based compensation | 58 | 57 | ||||||
Non-cash foreign exchange transaction gains | 314 | 549 | ||||||
Income taxes | (1 | ) | ||||||
Depreciation | 32 | 36 | ||||||
Non-GAAP net income (loss) adjusted for non-cash items | $ | 74 | $ | (600 | ) | |||
(3) Operating expenses minus non-cash expenses | ||||||||
GAAP operating expenses as reported | $ | 2,617 | $ | 2,559 | ||||
Non-cash adjustments: | ||||||||
Stock-based compensation | (58 | ) | (57 | ) | ||||
Depreciation | (32 | ) | (36 | ) | ||||
Non-GAAP operating expenses minus non-cash expenses | $ | 2,527 | $ | 2,466 | ||||
Loss from operations minus non-cash expenses EBITDA gain (loss) is a non-GAAP financial measure. The Company defines this as GAAP reported operating income (loss) minus operating depreciation and amortization and operating stock-based compensation. The Company uses this measure for the purpose of modifying the operating loss to reflect normal direct cash related transactions during the measurement period. Non-GAAP measures should not be considered a substitute for financial measures presented in accordance with GAAP. Non-GAAP measures are not always consistent across, or comparable with, non-GAAP measures disclosed by other companies.
Net loss adjusted for non-cash items and one-time events is a non-GAAP financial measure. The Company defines this as GAAP reported net loss minus depreciation and amortization, stock-based compensation, income taxes and non-cash foreign exchange transaction losses. The Company uses this measure for the purpose of modifying the net loss to reflect only those expenses to reflect normal direct cash transactions during the measurement period. Non-GAAP measures should not be considered a substitute for financial measures presented in accordance with GAAP. Non-GAAP measures are not always consistent across, or comparable with, non-GAAP measures disclosed by other companies.
Operating expenses minus non-cash expenses is a non-GAAP financial measure. The Company defines operating expenses minus non-cash expenses as GAAP reported operating expenses minus operating depreciation and amortization, and operating stock-based compensation. The Company uses this measure for the purpose of identifying total operating expenses involving cash transactions during the measurement period. Non-GAAP measures should not be considered a substitute for financial measures presented in accordance with GAAP. Non-GAAP measures are not always consistent across, or comparable with, non-GAAP measures disclosed by other companies.
SOURCE: Sonoma Pharmaceuticals, Inc.
View the original press release on ACCESS Newswire